Immunosuppression in Composite Tissue Allotransplantation

  • Bijan Eghtesad
  • John J. Fung


Composite tissue allotransplantation (CTA) is emerging as a new modality in reconstructive surgery as potential treatment for complex tissue, anatomic and functional defects. While the technical aspects of such procedures are constantly undergoing refinement, the practical issues due to the need and as a result, lifelong risks of exposure to the immunosuppressive drugs, remains as a major drawback. The implementation of induction and maintenance therapy protocols used in solid organ transplantation (SOT) has resulted in excellent patient and graft survival in CTA and has minimized the risk of graft loss due to uncontrolled rejection. Further understanding of the mechanisms and tempo of graft acceptance and rejection in CTA may lead to protocols that minimize the need for maintenance immunosuppressive therapy and as a result reduce the risk for long-term side effects.


Acute Rejection Immunosuppressive Agent Solid Organ Transplantation Mycophenolic Acid Mixed Chimerism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.





Antithymocyte globulin


Calcineurin inhibitors


Composite tissue allotransplantation




Hematopoietic stem cell




Mycophenolate mofetil


Mycophenolic acid




Solid organ transplantation




Therapeutic drug monitoring


  1. 1.
    Gilbert R. Transplant is successful with a cadaver forearm. Med Trib Med News. 1964;5:20-22.Google Scholar
  2. 2.
    Gilbert R. Hand transplanted from cadaver is re-amputated. Med Trib Med News. 1964;5:23.Google Scholar
  3. 3.
    A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med. 1983;309:809-815.Google Scholar
  4. 4.
    Calne RY, Rolles K, White DJ, et al. Cyclosporine A initially as only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet. 1979;2:1033-1036.PubMedCrossRefGoogle Scholar
  5. 5.
    Iwatsuki S, Starzl TE, Todo S, et al. Experience in 1000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc. 1988;20(1 suppl 1):498-504.PubMedGoogle Scholar
  6. 6.
    Press BH, Sibley RK, Shons AR, et al. Limb allotransplantation in rat: extended survival and return of nerve function with continuous cyclosporine/prednisone immunosuppression. Ann Plast Surg. 1986;16:313-321.PubMedCrossRefGoogle Scholar
  7. 7.
    Benhain P, Anthony JP, Ferreira L, et al. Use of combination of low-dose cyclosporine and RS-61443 in a rat hindlimb model of composite tissue allotransplantation. Transplantation. 1996;61:527-532.CrossRefGoogle Scholar
  8. 8.
    Dubernard JM, Owen E, Herzberg G, et al. Human hand allograft: report on first 6 months. Lancet. 1999;353:1315-1320.PubMedCrossRefGoogle Scholar
  9. 9.
    Dubernard JM, Lengele B, Morelon E, et al. Outcomes 18 months after the first human partial face transplantation. N Engl J Med. 2007;357:2451-2460.PubMedCrossRefGoogle Scholar
  10. 10.
    Fung J, Kelly D, Kadry Z, Patel-Tom K, Eghtesad B. Immunosuppression in liver transplantation: beyond calcineurin inhibitors. Liver Transplant. 2005;11:267-280.CrossRefGoogle Scholar
  11. 11.
    European FK. 506 multicenter liver study group. Randomized trial comparing tacrolimus and cyclosporine in prevention of liver allograft rejection. Lancet. 1994;344:423-428.CrossRefGoogle Scholar
  12. 12.
    Whitaker IS, Duggan EM, Alloway RR, et al. Composite tissue allotransplantation: a review of relevant immunological issues for plastic surgeons. J Plast Reconstr Aesthet Surg. 2008;61:481-492.PubMedCrossRefGoogle Scholar
  13. 13.
    Hadani H, Hettiaratchy S, Clarke A, et al. Immunosuppression in an emerging field of plastic and reconstructive surgery: composite tissue allotransplantation. J Plast Reconstr Aesthet Surg. 2008;61:245-249.CrossRefGoogle Scholar
  14. 14.
    Gordon C, Siemionow M, Papay F, et al. The world’s experience with facial transplantation: what have we learned thus far? Ann Plast Surg. 2009;63:572-578.PubMedCrossRefGoogle Scholar
  15. 15.
    Ravindra K, Buell J, Kaufman C, et al. Hand transplantation in the United States: experience with 3 patients. Surgery. 2008;144:638-644.PubMedCrossRefGoogle Scholar
  16. 16.
    Sigal NH, Dumont F, Durette P, et al. Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A? J Exp Med. 1991;173:619-628.PubMedCrossRefGoogle Scholar
  17. 17.
    Rabkin JM, Corless CL, Rosen HR, et al. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am J Surg. 2002;183:595-599.PubMedCrossRefGoogle Scholar
  18. 18.
    Fung JJ, Jain A, Kwak EJ, et al. De novo malignancies following liver transplantation – A major cause of death. Liver Transplant. 2001;7(Supp 1):S109-S118.CrossRefGoogle Scholar
  19. 19.
    Morgan JA. The influence of cortisone on the survival of homografts skin in the rabbit. Surgery. 1951;30:506-515.PubMedGoogle Scholar
  20. 20.
    Starzl TE, Marchioro TL, Waddell WR. The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. Surg Gynecol Obstet. 1963;117:385-395.PubMedGoogle Scholar
  21. 21.
    Murray JE, Merrill JP, Harrison JH, et al. Prolonged survival of human kidney homografts by immunosuppressive drug therapy. N Engl J Med. 1963;268:1315-1323.PubMedCrossRefGoogle Scholar
  22. 22.
    Jain A, Venkataramanan R, Hamad IS, et al. Pharmacokinetics of mycophenolic acid after mycophenolate mofetile administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol. 2001;41:268-276.PubMedCrossRefGoogle Scholar
  23. 23.
    Barkmann A, Nashan B, Schmidt HH, et al. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetile. Transplantation. 2000;69:1886-1890.PubMedCrossRefGoogle Scholar
  24. 24.
    Jain AB, Hamad I, Rakela J, et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetilein primary adult liver transplant recipients: an interim report. Transplantation. 1998;66:1395-1398.PubMedCrossRefGoogle Scholar
  25. 25.
    Trotter JF. Sirolimus in liver transplantation. Transplant Proc. 2003;35(suppl 3A):193S-299S.PubMedCrossRefGoogle Scholar
  26. 26.
    Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal transplant Study Group. Transplantation. 1999;67:1036-1042.PubMedCrossRefGoogle Scholar
  27. 27.
    King-Biggs MB, Cunitz JM, Park SJ, et al. Airway anastomotic dehiscence associated with the use of sirolimus immediately after lung transplantation. Transplantation. 2003;75:1437-1443.PubMedCrossRefGoogle Scholar
  28. 28.
    Rebellato LM, Gross U, Verbanac KM, et al. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulins. Transplantation. 2003;75:657-662.CrossRefGoogle Scholar
  29. 29.
    Michallet MC, Preville X, Flacher M, et al. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation. 2003;75:657-662.PubMedCrossRefGoogle Scholar
  30. 30.
    Calne RY, Friend P, Moffatt S, et al. Prope tolerance, perioperative Campath 1h, and low-dose cyclosporine monotherapy in renal allograft recipients. Lancet. 1998;351:1701-1702.PubMedCrossRefGoogle Scholar
  31. 31.
    Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (campath 1H). Transplantation. 2003;76:120-129.PubMedCrossRefGoogle Scholar
  32. 32.
    Schneeberger S, Landin L, Kaufmann C, et al. Alemtuzumab: key for minimization of maintenance immunosuppression in reconstructive transplantation. Transplant Proc. 2009;41:499-502.PubMedCrossRefGoogle Scholar
  33. 33.
    Emre S, Gondolesi G, Polat K, et al. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal; function. Liver Transplant. 2001;7:220-225.CrossRefGoogle Scholar
  34. 34.
    Guo S, Han Y, Zhang X, et al. Human facial allotransplantation: a 2-year follow-up study. Lancet. 2008;372:631-638.PubMedCrossRefGoogle Scholar
  35. 35.
    Lantieri L, Meningaud JP, Grimbert P, et al. Repair of the lower and middle part of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibromatosis: a 1-year follow-up study. Lancet. 2008;372:639-645.PubMedCrossRefGoogle Scholar
  36. 36.
    Siemionow M, Papay F, Alam D, et al. First US near-total human face transplantation – a paradigm shift for massive facial injuries. Lancet. 2009;374:203-209.PubMedCrossRefGoogle Scholar
  37. 37.
    Allen U, Avery RK, Blumberg E, Burroughs M, et al. Guidelines for the prevention and management of infectious complications of solid organ transplantation. Am J Transplant. 2004;4(Suppl 10):5-166.Google Scholar
  38. 38.
    Murray JE. Organ transplantation (skin, kidney, heart) and the plastic surgeon. Plast Reconstr Surg. 1971;47:425-431.PubMedCrossRefGoogle Scholar
  39. 39.
    Lee WP, Yaremchuk MJ, Pan YC, et al. Relative antigenicity of components of a vascularized limb allograft. Plast Reconstr Surg. 1991;87:401-411.PubMedCrossRefGoogle Scholar
  40. 40.
    Goldwyn RM, Beach PM, Felman D, et al. Canine limb homotransplantations. Plast Reconstr Surg. 1966;37:184-195.PubMedCrossRefGoogle Scholar
  41. 41.
    Mathes DW, Randolph MA, Solari MG, et al. Split tolerance to a composite tissue allogaft in swine model. Transplantation. 2003;75:25-31.PubMedCrossRefGoogle Scholar
  42. 42.
    Wang HJ, Ding YQ, Pei GX, et al. A preliminary pathological study on human allotransplantation. Chin J Traumatol. 2003;6:284-287.PubMedGoogle Scholar
  43. 43.
    Kanitakis J, Badet L, Petruzzo P, et al. Clinicopathologic monitoring of the skin and oral mucosa of the first human face allograft: report on the first eight months. Transplantation. 2006;82:1610-1615.PubMedCrossRefGoogle Scholar
  44. 44.
    Kanitakis J, Jullien D, Petruzzo P, et al. Clinicopathological features of graft rejection in the first human hand allograft. Transplantation. 2003;76:688-693.PubMedCrossRefGoogle Scholar
  45. 45.
    Kanitakis J. Skin rejection in human hand allografts: histologic findings and grading system. In: Lanzetta M, Dubernard JM, eds. Hand Transplantation. Milan, Italia: Springer-Verlag; 2007:249.CrossRefGoogle Scholar
  46. 46.
    Levi D, Tzakis A, Kato T, et al. Transplantation of the abdominal wall. Lancet. 2003;361:2173-2176.PubMedCrossRefGoogle Scholar
  47. 47.
    Cendales L, Kirk A, Moresi M, et al. Composite tissue allotransplantation: classification of clinical acute skin rejection. Transplantation. 2005;80:1676-1680.PubMedCrossRefGoogle Scholar
  48. 48.
    Demetris AJ, Murase N, Ye Q, et al. Analysis of chronic rejection and obliterative arteriopathy: possible contributions of donor antigen presenting cells and lymphatic disruption. Am J Pathol. 1997;150:563-578.PubMedGoogle Scholar
  49. 49.
    Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bome marrow leads to specific acceptance of allografts or xenografts. Nature. 1984;307:168-170.PubMedCrossRefGoogle Scholar
  50. 50.
    Burlingham WJ. Chimerism after organ transplantation: is there any clinical significance? Clin Transplant. 1996;10:110-117.PubMedGoogle Scholar
  51. 51.
    Starzl TE. Acquired immunogenic tolerance: with particular reference to transplantation. Immunol Res. 2007;38:6-41.PubMedCrossRefGoogle Scholar
  52. 52.
    Starzl TE, Zinkernagel RM. Transplantation tolerance from a historic perspective. Nat Rev Immunol. 2001;1:233-239.PubMedCrossRefGoogle Scholar
  53. 53.
    El Jaafari A, Badet L, Kanitakis J, et al. Isolation of regulatory T cells in the skin of a human hand allograft, up to six years posttransplantation. Transplantation. 2006;82:1764-1768.CrossRefGoogle Scholar
  54. 54.
    Trivedi HL, Vanikar AV, Modi PR, et al. Allogeneic hematopoietic stem-cell transplantation, mixec chimerism, and tolerance in living related donor renal allograft recipients. Transplant Proc. 2005;37:737-742.PubMedCrossRefGoogle Scholar
  55. 55.
    Granger DK, Briedenbach WC, Pidwell DJ, et al. Lack of donor hyporesponsiveness and donor chimerism after clinical transplantation of the hand. Transplantation. 2002;74:1624-1630.PubMedCrossRefGoogle Scholar

Copyright information

© Springer London 2011

Authors and Affiliations

  1. 1.Department of HPB/Liver Transplant SurgeryCleveland ClinicClevelandUSA

Personalised recommendations